SCHEMBL15782856

SCHEMBL15782856

CCc1cc2cccc(OC)c2c(OC)c1C(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
NPC1 O15118 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.43
RECQL P46063 2/20 0.43
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
RAB9A P51151 2/20 0.40
PDE10A Q9Y233 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15782863 0.86 MAPT (0.45) MAPTNPC1LMNARECQLKMT2A
SCHEMBL15782862 0.81 USP2 (0.48) MAPTSMN1; SMN2RECQLKMT2AKDM4E
SCHEMBL18489535 0.74 SMN1; SMN2 (0.45) MAPTNPC1SMN1; SMN2LMNARECQL
SCHEMBL3660039 0.74 CA12 (0.55) SMN1; SMN2KMT2AMEN1CA12CA1
SCHEMBL12627536 0.73 SMN1; SMN2 (0.58) MAPTNPC1SMN1; SMN2LMNAKMT2A
SCHEMBL12948359 0.72 HIF1A (0.50) MAPTSMN1; SMN2RECQLKMT2ACA12
SCHEMBL20020937 0.71 MAPT (0.47) MAPTLMNARECQLCA12CA1
SCHEMBL15782873 0.71 MEN1 (0.50) MAPTRECQLKMT2AMEN1CA12
SCHEMBL4948691 0.71 ALDH1A1 (0.46) MAPTKMT2AMEN1CA12KDM4E
SCHEMBL22967810 0.70 KDM4E (0.50) MAPTNPC1SMN1; SMN2LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3138831-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF President and Fellows of Harvard College (US) 2017-03-08 EP disclosed
US-20160340325-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-11-24 US disclosed
US-9365493-B2 Synthesis of tetracyclines and analogues thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-06-14 US disclosed
US-20140163238-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163238-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF TET1, TET3, MYC MAPT 990/4885NPC1 3339/4885SMN1; SMN2 3539/4885
US-20160340325-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF TET1, TET3, MYC MAPT 990/4885NPC1 3339/4885SMN1; SMN2 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.